Initial Feasibility Study definition

Initial Feasibility Study means an initial Mineral Reserve estimate and mine plan Former LAC completed on the Cauchari-Olaroz in 2012;
Sample 1Sample 2Sample 3
Initial Feasibility Study means the study and preparation work undertaken by FRESENIUS for TRANSMEDICS pursuant to and under the Letter of Intent.
Sample 1Sample 2Sample 3
Initial Feasibility Study or "Prefeasibility Study" means a study of the feasibility of developing and operating a mine on the Properties, including an analysis of economic, engineering, geological, environmental, regulatory and other considerations, and containing the level of detail customary in the industry to determine whether the veins, ore bodies or other targets identified in Stage I of Earn-in Activities are of sufficient interest to the Parties to proceed with Stage II of Earn-in Activities (with all estimates developed to an accuracy within +/-15%).
Sample 1

Examples of Initial Feasibility Study in a sentence

  • The FSU assumed the development of the Agua Rica deposit on an independent basis and was based on the 1997 BHP/Northern Orion Initial Feasibility Study and recent additional work undertaken by the Company.

  • Proposed Programs and Budgets shall be prepared by the Manager in consultation with the other Participants, and must cover a period of six (6) months until the delivery of an Initial Feasibility Study and for one (1) year periods thereafter unless otherwise agreed by the Management Committee.

  • If the revision would increase the capital expenditures contemplated in the Initial Feasibility Study by more than 25%, the revision shall be treated as a proposal requiring a unanimous decision of the Management Committee as provided in Section 7.2(b)(vii).

  • Subject to Article 7.3, if and when an Initial Feasibility Study has been delivered to SOTRAPMAG and the Management Committee, together with a written notice (the "Notice of Vesting") from ASARCO that it wishes to exercise its option and be vested with 50% of SOTRAPMAG's Participating Interest in a Joint Venture, ASARCO shall be deemed to be vested with a Participating Interest in such Joint Venture equal to 50% of SOTRAPMAG's Participating Interest in such Joint Venture as of that date.

  • If the revision would increase the capital expenditures contemplated in the Initial Feasibility Study by 25% or less, Hecla may elect to participate in the additional capital expenditures, or to participate only to the extent of its participation as originally elected for the Initial Program and Budget (in which case it shall be subject to dilution based upon its election not to contribute to the additional capital expenditures under the revision).

  • The scope, timing and preparation of the Initial Feasibility Study on a Property shall be determined solely by ASARCO (or, if ASARCO no longer has a Participating Interest in the Joint Venture relating to such Property, by the Participant who has the highest Participating Interest in such Joint Venture), and its preparation shall be included in corresponding Adopted Programs and Budgets adopted by the Management Committee of such Joint Venture.

  • The FSU assumes the development of the Agua Rica deposit on an independent basis and is based on the 1997 BHP/Northern Orion Initial Feasibility Study and recent additional work undertaken by Northern Orion.

  • After the Management Committee of such Joint Venture has adopted its first Adopted Program and Budget, pay to SOTRAPMAG or as SOTRAPMAG directs, SOTRAPMAG's share of all Expenditures to complete Exploration as provided for in the Adopted Programs and Budgets of such Joint Venture and such other expenses as are approved by the Management Committee of such Joint Venture, including the cost of the Initial Feasibility Study on the Property of such Joint Venture, but subject to the provisions of this Article.

  • Any Participant may propose to the Management Committee at any time that a Feasibility Study, in addition to the Initial Feasibility Study, evaluate the feasibility of opening or expanding a mine on a particular area of the Properties be conducted on behalf of the Venture.

  • In the event such Initial Feasibility Study has not been completed and ASARCO has commissioned the preparation of such Initial Feasibility Study by the fifth anniversary of the Effective Date, then the time for completing such Initial Feasibility Study will be extended for six months to allow it to be completed.


More Definitions of Initial Feasibility Study

Initial Feasibility Study means the Feasibility Study delivered pursuant to Section 5.5 of the Earn-in Agreement.
Sample 1
Initial Feasibility Study means, in relation to a particular proposal for a management agreement, a study carried out by an approved person to determine whether it is reasonable to proceed with a full feasibility study;
Sample 1
Initial Feasibility Study means a Feasibility Study prepared for either of the Joint Ventures in respect of a Primary Deposit on either the Paul Isnard Concessions or the Eau Blanche Permits which reaches one of the following conclusions:
Sample 1

Related to Initial Feasibility Study

  • Feasibility Study means the evaluation and analysis of the potential of a project, which aims at supporting the process of decision-making by objectively and rationally uncovering its strengths and weaknesses, opportunities and threats, as well as identifying the resources required to carry it through and ultimately its prospects for success;

  • Interconnection Feasibility Study means either a Generation Interconnection Feasibility Study or Transmission Interconnection Feasibility Study.

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Generation Interconnection Feasibility Study means a study conducted by the Transmission Provider (in coordination with the affected Transmission Owner(s)) in accordance with Tariff, Part IV, section 36.2.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Phase I Clinical Trial means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(a) or its foreign equivalents.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Development Phase means the period before a vehicle type is type approved.

  • Mitigation Study Period means the duration of time extending six consecutive Capability Periods and beginning with the Starting Capability Period associated with a Class Year Study, Additional SDU Study, and/or Expedited Deliverability Study. For purposes of Section 23.4.5 of this Attachment H, “Mitigated UCAP” shall mean one or more megawatts of Unforced Capacity that are subject to Control by a Market Party that has been identified by the ISO as a Pivotal Supplier. For purposes of Section 23.4.5 of this Attachment H, “Mitigation Net CONE” shall mean the capacity price on the currently effective ICAP Demand Curve for the Mitigated Capacity Zone corresponding to the average amount of excess capacity above the Mitigated Capacity Zone Installed Capacity requirement, expressed as a percentage of that requirement, that formed the basis for the ICAP Demand Curve approved by the Commission.

  • Development Report means a written account of Licensee’s progress under the Development Plan having at least the information specified on Appendix B to this Agreement, and shall be sent to the address specified on Appendix B.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.

  • Phase 4 Clinical Trial means a Clinical Study in any country which is conducted after Regulatory Approval of a product has been obtained from an appropriate Regulatory Authority, consisting of trials conducted voluntarily for enhancing marketing or scientific knowledge of an approved indication and trials conducted due to request or requirement of a Regulatory Authority.

  • Study Completion means the database for the Study has been locked and all Essential Documents have been provided to the Sponsor, including a copy of the letter from the Reviewing HREC acknowledging receipt of the final report and/or closure letter from the Principal Investigator.

  • Phase II Study means a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Development Plan has the meaning set forth in Section 3.2.

  • Development Site means any parcel or lot on which exists or which is intended for building development other than the following:

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Phase III means Phase I (or Phase I/II), Phase II (or Phase II/III) and Phase III clinical trials, respectively, in each case as prescribed by applicable FDA IND Regulations, or any corresponding foreign statutes, rules or regulations.

  • Clinical Study means a Phase I Study, Phase II Study, Phase III Study, as applicable.

  • Phase III Clinical Trial means a large, controlled or uncontrolled Clinical Study that would satisfy the requirements of 21 CFR 312.21(c), intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.